Rheumatology

Do Inadequate Storage Practices Play a Role in Loss of Response to Subcutaneous Biologic Agents?

January 29th 2018

By Jackie Syrop

A recent study, set in the Netherlands, sought to assess patients’ attitudes about redistributing unused, subcutaneously administered biologic drugs, which could allow potential cost savings for the health system. However, the study unexpectedly found alarming storage inconsistencies and patient nonadherence to storage guidelines for these drugs.

ACR Symposium Highlights Approaches to Using Biologics, Biosimilars in RA

January 25th 2018

By Samantha DiGrande

At the American College of Rheumatology (ACR)'s Winter Rheumatology Symposium, held this week in Snowmass Village, Colorado, rheumatologists from across the country gathered to discuss the latest approaches to treating rheumatoid arthritis (RA).

Pfizer's PF-05280586 Shows Equivalence to Reference Rituximab in Comparative Study

January 24th 2018

By Jackie Syrop

Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.

Putting Patients at the Center of the Biosimilar Conversation

January 24th 2018

Oncology Biosimilars Making a Difference for Patients

January 24th 2018

The FDA and Diversity in Clinical Trials

January 24th 2018

Diversity in Clinical Trials for Biosimilars

January 24th 2018

Manufacturers and the Cost of Biosimilars and Biologics

January 24th 2018

Patient Assistance Programs and Biosimilars

January 24th 2018

Biosimilars, Private Payers, and Pharmacy-Level Substitution

January 24th 2018